Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy, safety, and tolerability of USL261 compared
with that of intranasal (IN) placebo for the treatment of intermittent bouts of increased
seizure activity.